Paratek Pharmaceuticals (PRTK) Form 3/A Paratek Pharmaceuticals / Randall B. Brenner ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Brenner Randall B.

(Last) (First) (Middle)

C/O PARATEK PHARMACEUTICALS, INC.

75 PARK PLAZA, 3RD FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/17/2019

3. Issuer Name and Ticker or Trading Symbol
Paratek Pharmaceuticals, Inc. [ PRTK ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Development & Regulatory

5. If Amendment, Date of Original Filed (Month/Day/Year)
09/27/2019

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,000(1)	D
Common Stock	15,000(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were omitted from the Reporting Person's original Form 3, and were also omitted from subsequent Form 4s filed by the Reporting Person after his original Form 3 was filed. Represents performance-based restricted stock units ("PRSUs") granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, which were earned on October 2, 2018. These PRSUs settled in shares of Common Stock on October 2, 2019.

2. These shares were omitted from the Reporting Person's original Form 3, and were also omitted from subsequent Form 4s filed by the Reporting Person after his original Form 3 was filed. Represents PRSUs granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, which were earned on February 1, 2019. These PRSUs settled in shares of Common Stock on May 8, 2020.

	/s/ William M. Haskel, Attorney-in-Fact for Randall B. Brenner	06/06/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.